Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir exalidex - Hepion Pharmaceuticals

Drug Profile

Tenofovir exalidex - Hepion Pharmaceuticals

Alternative Names: CMX-157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; lipid conjugate TFV(tenofovir); Lipid conjugate YTFV; TXL

Latest Information Update: 05 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chimerix
  • Developer Chimerix; Hepion Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 22 Jul 2019 ContraVir Pharmaceuticals is now called Hepion Pharmaceuticals
  • 09 Nov 2018 Updated pharmacokinetics data from a phase I trial in Hepatitis B presented at the 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2018)
  • 06 Aug 2018 Tenofovir exalidex - ContraVir Pharmaceuticals is available for licensing in USA, Europe as of 06 Aug 2018. www.contravir.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top